Literature DB >> 9671438

Microfibril-associated glycoprotein-2 (MAGP-2) is specifically associated with fibrillin-containing microfibrils but exhibits more restricted patterns of tissue localization and developmental expression than its structural relative MAGP-1.

M A Gibson1, M L Finnis, J S Kumaratilake, E G Cleary.   

Abstract

We developed an affinity-purified anti-MAGP-2 peptide antibody that specifically identified MAGP-2 on Western blots of purified matrix proteins and extracts of nuchal ligament. Immunolocalization studies on tissues from a 210-day-old fetus and a mature bovine showed that MAGP-2 was located in similar regions to MAGP-1 and fibrillin-1 but that the distribution of MAGP-2 was more restricted. In fetal nuchal ligament, skeletal muscle, and spleen the distribution of MAGP-2 was indistinguishable from that of MAGP-1. In contrast to MAGP-1, MAGP-2 was not detected in the medial layer of fetal thoracic aorta and in much of the peritubular matrix of fetal and mature kidney and in the mature ocular zonule. Some differences in the immunolocalization patterns were also evident in fetal lung, cartilage, skin, and heart. Immunoelectron microscopy confirmed that MAGP-2 was specifically associated with fibrillin-containing microfibrils in nuchal ligament, dermis, adventitia of aorta, glomerular mesangium and perimysium. Northern blotting of RNA from tissues of a 210-day-old fetus indicated that steady-state MAGP-2 mRNA levels were highest in nuchal ligament. Significant expression was also detected in lung, heart, skeletal muscle, skin, and Achilles tendon. The tissue pattern of MAGP-2 expression differed significantly from that of MAGP-1. MAGP-2 expression appeared to be higher in nuchal ligament, heart, and skeletal muscle and lower in aorta and kidney. In nuchal ligament, MAGP-2 mRNA expression appeared to peak around 180 days of fetal development, which correlates with the period of onset of elastinogenesis in this tissue. Overall, the immunolocalization and expression patterns of MAGP-2 appeared to be distinct from those of other microfibrillar components. This is consistent with the view that MAGP-2 plays a unique role in the biology of the microfibrils, perhaps by mediating their interaction with cell surfaces at specific stages of development and differentiation. (J Histochem Cytochem 46:871-885, 1998)

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671438     DOI: 10.1177/002215549804600802

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  24 in total

1.  Muscle fibrillin deficiency in Marfan's syndrome myopathy.

Authors:  W M H Behan; C Longman; R K H Petty; P Comeglio; A H Child; M Boxer; P Foskett; D G F Harriman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

Review 2.  Fibrillin-rich microfibrils: elastic biopolymers of the extracellular matrix.

Authors:  C M Kielty; T J Wess; L Haston; Jane L Ashworth; M J Sherratt; C A Shuttleworth
Journal:  J Muscle Res Cell Motil       Date:  2002       Impact factor: 2.698

Review 3.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

4.  Human microvascular lymphatic and blood endothelial cells produce fibrillin: deposition patterns and quantitative analysis.

Authors:  Antonella Rossi; Erica Gabbrielli; Marilisa Villano; Mario Messina; Francesco Ferrara; Elisabetta Weber
Journal:  J Anat       Date:  2010-10-11       Impact factor: 2.610

Review 5.  Vascular extracellular matrix and arterial mechanics.

Authors:  Jessica E Wagenseil; Robert P Mecham
Journal:  Physiol Rev       Date:  2009-07       Impact factor: 37.312

6.  Identification of the chondrocyte lineage using microfibril-associated glycoprotein-2, a novel marker that distinguishes chondrocytes from synovial cells.

Authors:  Stephen Rapko; Mindy Zhang; Brenda Richards; Elizabeth Hutto; Sandra Dethlefsen; Stephen Duguay
Journal:  Tissue Eng Part C Methods       Date:  2010-05-10       Impact factor: 3.056

7.  Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis.

Authors:  Lijun Wang; Liang Zhou; Peiyong Jiang; Leina Lu; Xiaona Chen; Huiyao Lan; Denis C Guttridge; Hao Sun; Huating Wang
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

8.  Characterization of the renal phenotype in a mouse model of Marfan syndrome.

Authors:  Andrea Hartner; Timo Eifert; Christian S Haas; Cigdem Tuysuz; Karl F Hilgers; Dieter P Reinhardt; Kerstin Amann
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

9.  Deficiency in microfibril-associated glycoprotein-1 leads to complex phenotypes in multiple organ systems.

Authors:  Justin S Weinbaum; Thomas J Broekelmann; Richard A Pierce; Claudio C Werneck; Fernando Segade; Clarissa S Craft; Russell H Knutsen; Robert P Mecham
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

10.  Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo.

Authors:  Michelle D Combs; Russell H Knutsen; Thomas J Broekelmann; Holly M Toennies; Thomas J Brett; Chantel A Miller; Daniel L Kober; Clarissa S Craft; Jeffrey J Atkinson; J Michael Shipley; Barbara C Trask; Robert P Mecham
Journal:  J Biol Chem       Date:  2013-08-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.